Royalty Pharma plc has completed the acquisition of its external manager, RP Management, LLC, marking a significant milestone for the company. This transaction, which received 99.9% shareholder approval, transitions Royalty Pharma from an external management model to an internalized structure. All employees of RP Management have now become employees of Royalty Pharma. This move is expected to enhance shareholder value through improved governance and reduced costs, while better positioning the company to support innovation in the life sciences industry. Royalty Pharma will update its full-year 2025 guidance to reflect this change when it reports its second quarter 2025 financial results.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。